Switch theme
Sign up to access all valuation multiples
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
1991
243
LTM Revenue n/a
LTM EBITDA n/a
$30.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CASI Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, CASI Pharmaceuticals achieved revenue of $33.9M and an EBITDA of -$21.5M.
CASI Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CASI Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $33.9M | n/a | XXX | XXX | XXX |
| Gross Profit | $17.6M | $27.3M | XXX | XXX | XXX |
| Gross Margin | 52% | NaN% | XXX | XXX | XXX |
| EBITDA | -$21.5M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -64% | NaN% | XXX | XXX | XXX |
| Net Profit | -$36.7M | -$41.0M | XXX | XXX | XXX |
| Net Margin | -108% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, CASI Pharmaceuticals's stock price is $2.
CASI Pharmaceuticals has current market cap of $32.1M, and EV of $30.4M.
See CASI Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30.4M | $32.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, CASI Pharmaceuticals has market cap of $32.1M and EV of $30.4M.
CASI Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate CASI Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for CASI Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $30.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCASI Pharmaceuticals's NTM/LTM revenue growth is n/a
CASI Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, CASI Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate CASI Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for CASI Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 49% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 75% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 134% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CASI Pharmaceuticals acquired XXX companies to date.
Last acquisition by CASI Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . CASI Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was CASI Pharmaceuticals founded? | CASI Pharmaceuticals was founded in 1991. |
| Where is CASI Pharmaceuticals headquartered? | CASI Pharmaceuticals is headquartered in United States of America. |
| How many employees does CASI Pharmaceuticals have? | As of today, CASI Pharmaceuticals has 243 employees. |
| Who is the CEO of CASI Pharmaceuticals? | CASI Pharmaceuticals's CEO is Dr. Wei-Wu He. |
| Is CASI Pharmaceuticals publicy listed? | Yes, CASI Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of CASI Pharmaceuticals? | CASI Pharmaceuticals trades under CASI ticker. |
| When did CASI Pharmaceuticals go public? | CASI Pharmaceuticals went public in 1996. |
| Who are competitors of CASI Pharmaceuticals? | Similar companies to CASI Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of CASI Pharmaceuticals? | CASI Pharmaceuticals's current market cap is $32.1M |
| Is CASI Pharmaceuticals profitable? | Yes, CASI Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
